Portal de investigación
Long-term effectiveness and safety of vedolizumab (VDZ) in inflammatory bowel disease (IBD): Results from the Spanish ENEIDA Registry
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Garre, A
- Alfaro, I
- Mesonero, P
- Mendoza, IV
- Miquel-Cusachs, J
- Riestra, S
- Navarro, P
- Parga, LD
- Gonzalez-Mnnoza, C
- Tirado, MR
- Manosa, M
- Salazar, LF
- Garcia-Sepulcre, M
- Guardiola, J
- Cabriada, J
- Casbas, AG
- Sicilia, B
- Calle, JLP
- Piqueras, M
- Guerra, I
- Roncero, O
- Navarro-Llavat, M
- Sainz, E
- Barrio, J
- Calvet, X
- Garcia, A
- Barrio, ML
- Lorente, R
- Almela, P
- Madrigal, R
- Villarin, AJL
- Pajares, R
- Van Domselaar, M
- Gil, JL
- Gisbert, JP
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Chaparro,M,Garre,A,Alfaro,I,Iborra,M,Mesonero,P,Mendoza,IV,Rodriguez,A et al. Long-term effectiveness and safety of vedolizumab (VDZ) in inflammatory bowel disease (IBD): Results from the Spanish ENEIDA Registry. GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND:OXFORD UNIV PRESS. 2018 p.p. 447-448.